View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 8, 2020

FDA authorises Emory University to trial antiviral for Covid-19

Emory University subsidiary DRIVE has received the US Food and Drug Administration (FDA) approval for its investigational new drug application of antiviral compound EIDD-2801 to treat Covid-19.

Emory University subsidiary DRIVE has received the US Food and Drug Administration (FDA) approval for its investigational new drug application of antiviral compound EIDD-2801 to treat Covid-19.

The approval allows human clinical trials by Ridgeback Biotherapeutics in the US. Ridgeback Biotherapeutics exclusively licensed the compound.

Discovered and developed by the university, EIDD-2801 is an orally available compound that works by preventing the replication of SARS-CoV-2.

In animal models, the drug candidate demonstrated activity against SARS-CoV and MERS-CoV. EIDD-2801 is also capable of activity against several diseases, including Ebola, influenza, chikungunya and equine encephalitis.

Emory University subsidiary DRIVE CEO George Painter said: “FDA’s prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible.

“We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting Covid-19.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU